
Psychedelic Drugs: Global Market Outlook
Report Highlights
The report provides an overview of the global psychedelic drugs market. This report includes sales forecasts and trends in the market for psychedelic drugs through 2027. It discusses leading companies in the market, product segments, supporting technologies, market dynamics, competitive intelligence and regional trends.
Report Includes
- 12 data tables and 9 additional tables
- A brief general outlook of the global market for psychedelic drugs within the biopharmaceutical industry
- Analyses of the global market trends, with historic sales data for 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the current and future market potential of psychedelic drugs, along with detailed analyses of the competitive environment, regulatory scenario, pipeline analysis, technological advancement and market dynamics
- Estimation of the actual market size and revenue forecast for global psychedelic drugs market in USD million values, and corresponding market share analysis based on drug type, application, and region
- Information on stringent regulatory policies and government guidelines to impede the adoption rate of the psychedelic drugs
- Review of key marketed and pipelined products indicated for different therapeutic applications, clinical trials, and penetration of technologies and research initiatives within the ecosystem
- Company profiles of major players within the industry, including Pfizer Inc., Celon Pharma, Cybin Corp., Jazz Pharmaceuticals Inc., and PharmaTher Holdings Ltd.
Report Scope
This report includes sales forecasts and trends in the market for psychedelic drugs through 2027. It discusses leading companies in the market, product segments, supporting technologies, market dynamics, competitive intelligence and regional trends. It also discusses market the competitive scenarios that will form the base data for qualitative analysis and market estimates.
In this report, the global market for psychedelic drugs is segmented into four geographic regions: North America, Europe, Asia and RoW (South America, the Middle East and Africa).
Frequently Asked Questions (FAQs)
- Growing scientific support for the development of psychedelic drugs
- Regulatory advancements
- Increasing patient and physician acceptance
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Synopsis
Report Metrics | Details |
---|---|
Base year considered | 2021 |
Forecast period considered | 2022-2027 |
Base year market size | $3.6 billion |
Market size forecast | $5.6 billion |
Growth rate | CAGR of 7.5% for the forecast period of 2022-2027 |
Units considered | $ Millions |
Segments covered | Drug Type, Application, Region |
Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) |
Key Market Drivers |
|
Companies studied | CELON PHARMA S.A. , CYBIN CORP. , HIKMA PHARMACEUTICALS PLC. , JAZZ PHARMACEUTICALS INC. , MIND MEDICINE INC. , PFIZER INC. , PHARMATHER HOLDINGS LTD. , REVIVE THERAPEUTICS LTD. |